XML 21 R35.htm IDEA: XBRL DOCUMENT v3.20.1
Significant Agreements - Roche License Agreement (Details) - USD ($)
1 Months Ended 3 Months Ended 12 Months Ended
Jun. 30, 2017
May 31, 2014
Feb. 28, 2014
Mar. 31, 2020
Mar. 31, 2019
Dec. 31, 2018
Dec. 31, 2019
License Agreement [Line Items]              
Collaboration revenue       $ 141,000 $ 186,000    
Accounts receivable       $ 174,000     $ 68,000
Collaborative Arrangement [Member]              
License Agreement [Line Items]              
License agreement, portion of revenue and expenses attributable to company, percentage       30.00%      
Roche [Member]              
License Agreement [Line Items]              
Revenue, remaining performance obligation, amount       $ 0     0
License agreement, development services, payment term       45 days      
License agreement, milestone payments, payment term       45 days      
Roche [Member] | Royalty Bearing License [Member]              
License Agreement [Line Items]              
Allocated consideration to performance obligations       $ 48,900,000      
ASC 605 allocated consideration to deliverables       35,600,000      
Roche [Member] | IND and Development Services [Member]              
License Agreement [Line Items]              
Allocated consideration to performance obligations       4,600,000      
ASC 605 allocated consideration to deliverables       3,300,000      
Roche [Member] | Supply Services [Member]              
License Agreement [Line Items]              
Allocated consideration to performance obligations       600,000      
ASC 605 allocated consideration to deliverables       400,000      
Roche [Member] | Clinical Product Supply [Member]              
License Agreement [Line Items]              
Allocated consideration to performance obligations       1,100,000      
ASC 605 allocated consideration to deliverables       800,000      
Roche [Member] | Collaborative Arrangement [Member]              
License Agreement [Line Items]              
Collaboration revenue, license, upfront payment     $ 30,000,000        
Milestone payment received, clinical milestone   $ 15,000,000          
Milestone achievement, clinical milestone $ 30,000,000            
License agreement, potential payment upon achievement of development, regulatory and various first commercial sales milestones       350,000,000      
License agreement, potential payment for achievement of non U.S. commercial sales milestones       $ 175,000,000      
License agreement, cost allocation, percentage       100.00%      
License agreement, portion of revenue and expenses attributable to company, percentage       70.00%      
License agreement, potential alternative commercial sales milestones       $ 155,000,000      
License agreement, initial transaction price       55,100,000      
Cost sharing payments recognized as research and development expense       3,900,000 $ 2,800,000    
Accounts receivable       2,000     $ 2,000
Roche [Member] | Collaborative Arrangement [Member] | Royalty Bearing License [Member]              
License Agreement [Line Items]              
License agreement, initial transaction price       45,000,000      
Roche [Member] | Collaborative Arrangement [Member] | IND and Development Services [Member]              
License Agreement [Line Items]              
License agreement, initial transaction price       9,100,000      
Roche [Member] | Collaborative Arrangement [Member] | Supply Services [Member]              
License Agreement [Line Items]              
License agreement, initial transaction price       1,100,000      
Roche [Member] | Development Costs Reimbursement [Member]              
License Agreement [Line Items]              
Development reimbursement           $ 1,000,000  
Roche [Member] | Research Reimbursement [Member]              
License Agreement [Line Items]              
Revenue, remaining performance obligation, amount       $ 0